Transmembrane protein 100 is expressed in neurons and glia of dorsal root ganglia and is reduced after painful nerve injury

Hongwei Yu\textsuperscript{a,b,*}, Seung Min Shin\textsuperscript{a}, Fei Wang\textsuperscript{a,c}, Hao Xu\textsuperscript{a,d}, Hongfei Xiang\textsuperscript{a,d}, Yongsong Cai\textsuperscript{a,e}, Brandon Itson-Zoske\textsuperscript{a}, Quinn H. Hogan\textsuperscript{a,b}

Abstract

Introduction: Tmem100 modulates interactions between TRPA1 and TRPV1. The cell specificity of Tmem100 expression in dorsal root ganglia (DRGs) is not well defined, nor is the effect of peripheral nerve injury on Tmem100 expression.

Objective: This study was designed to determine the cell specificity of Tmem100 expression in DRG and its subcellular localization, and to examine how Tmem100 expression may be altered in painful conditions.

Methods: Dorsal root ganglion Tmem100 expression was determined by immunohistochemistry, immunoblot, and quantitative real-time PCR, and compared between various experimental rat pain models and controls.

Results: Tmem100 is expressed in both neurons and perineuronal glial cells in the rat DRG. The plasma membrane and intracellular localization of Tmem100 are identified in 83% ± 6% of IB4-positive and 48% ± 6% of calcitonin gene-related peptide–positive neurons, as well as in medium- and large-sized neurons, with its immunopositivity colocalized to TRPV1 (94% ± 5%) and TRPA1 (96% ± 3%). Tmem100 is also detected in the perineuronal satellite glial cells and in some microglia. Tmem100 protein is significantly increased in the lumbar DRGs in the complete Freund adjuvant inflammatory pain. By contrast, peripheral nerve injury by spinal nerve ligation diminishes Tmem100 expression in the injured DRG, with immunoblot and immunohistochemistry experiments showing reduced Tmem100 protein levels in both neurons and satellite glial cells of DRGs proximal to injury, whereas Tmem100 is unchanged in adjacent DRGs. The spared nerve injury model also reduces Tmem100 protein in the injured DRGs.

Conclusion: Our data demonstrate a pain pathology–dependent alteration of DRG Tmem100 protein expression, upregulated during CFA inflammatory pain but downregulated during neuropathic pain.

Keywords: Transmembrane protein 100, Dorsal root ganglia, Primary sensory neurons, Satellite glial cells, Microglia, Inflammatory pain, Neuropathic pain

1. Introduction

Peripheral nerve injury often causes chronic neuropathic pain, for which the specific underlying mechanisms typically are uncertain, and available therapies are currently inadequate.\textsuperscript{6} Pain perception results from the generation of action potential trains in the periphery, which are conveyed to the central nervous system (CNS) by primary sensory neurons, which have cell bodies in the dorsal root ganglion (DRG). Nerve injury–induced malfunction of the primary sensory neurons and surrounding glial cells is a well-established source of chronic neuropathic pain.\textsuperscript{13} Identification of the altered gene expression and associated molecular pathways involving primary sensory neurons and glial cells that lead to neuropathic pain will be required for successful generation of specific analgesic therapies.

Transmembrane protein 100 (Tmem100) is a recently identified pain-signaling modulator expressed by DRG nociceptive neurons, which is found in regulating pain sensation by modulating association of TRPA1 and TRPV1,\textsuperscript{59} both of which are important...
mediators of pain in sensory pathways. Tmem100 modulates TRPA1 activity by decreasing TRPA1–TRPV1 interaction. Tmem100 deletion selectively in sensory neurons leads to a reduced TRPA1 but not TRPV1-mediated mechanical hyperalgesia in mouse inflammation pain. Also, a short TRPA1-binding peptide derived from the Tmem100 protein C-termminus shows analgesic in models of inflammatory pain and chemotherapy-induced pain in mice. These results demonstrate the complex and divergent influences of Tmem100 and associated signal transduction pathways in modulating pain and reveal them as potential targets for pain therapy.

Tmem100 is reported to be predominantly localized in calcitonin gene-related peptide (CGRP)-positive peptidergic neurons in mouse DRG and trigeminal ganglia, in which its expression is increased in inflammatory pain. However, the influence of painful peripheral nerve injury upon Tmem100 expression has not been determined. Gene expression during neuropathic and inflammatory pain can be distinct. For instance, IB4- and CGRP-positive small-sized DRG neurons are either functionally activated or increased in proportion in various inflammatory pain models. Complete Freund adjuvant (CFA) inflammation increases CGRP in the innervating DRG, and the proportion and size of DRG neurons with detectable CGRP expression after inflammation. By contrast, IB4- and CGRP-positive small-sized DRG neurons are either functionally activated or increased in proportion in various inflammatory pain models.

This study was designed to address these gaps in understanding the role of Tmem100 in painful conditions, and also to consider the therapeutic potential of Tmem100 as a target for treating chronic neuropathic pain. Because the cell specificity of Tmem100 expression has not been fully examined, we determined Tmem100 expression in the different cell populations of adult rats. We further characterized Tmem100 expression in the CFA-inflammatory pain model and in peripheral nerve injury–induced neuropathic pain in rats. We found Tmem100 protein expression in the full range of primary sensory neuron populations in adult DRG. Tmem100 is also robustly detected in the perineuronal satellite glial cells (SGCs) and a few microglia. Pain induces alteration of Tmem100 expression in a pathology-dependent manner, upregulated after CFA-inflammatory pain but dramatically downregulated in the injured DRGs after peripheral nerve injury.

2. Methods

2.1. Animals

Adult male Sprague–Dawley rats weighing 100 to 125 g body weight (Charles River Laboratories, Wilmington, MA) were used. All animal experiments were performed with the approval of the Zablocki VA Medical Center Animal Studies Subcommittee and Medical College of Wisconsin Institutional Animal Care and Use Committee (Permit number: 3690-03) in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Animals were housed individually in a room maintained at constant temperature (22 ± 0.5°C) and relative humidity (60% ± 15%) with an alternating 12-hour light–dark cycle. Animals were given ad libitum access to water and food throughout the experiment, and all efforts were made to minimize suffering.

2.2. Generation of experimental rat pain models

Inflammatory pain was induced by subcutaneous intraplantar injection of a single dose of CFA, performed as described previously. In brief, on day 0, after baseline behavior testing (von Frey, Pin, and Heat), rats were anesthetized briefly with isoflurane (4% induction and 2% maintenance), and their right foot was swabbed with ethanol, followed by injection of 100 μL of CFA (Sigma-Aldrich, St. Louis, MO) at a concentration of 1.0 mg/mL or saline subcutaneously in the plantar surface of the right hind paw. Behavior was evaluated thereafter every 2 days until 10 days after CFA.

Two rat neuropathic pain models were used, the spinal nerve ligation (SNL) at the fifth lumbar (L5) level and the spared nerve injury (SNI) model. These were performed as previously described. Briefly, after baseline behavior testing (von Frey, Pin, and Heat), for unilateral right SNL, the right lumbar paravertebral region was exposed through a midline incision, and the L5 transverse process was removed to expose the L5 spinal nerve, which was then ligated with 6-0 silk sutures and severed approximately 5 mm distal to L5 DRG. To perform unilateral right SNL, an incision was made on the lateral midthigh, and the underlying muscles were separated to expose the right sciatic nerve, whereupon the tibial and common peroneal were individually ligated with 6-0 sutures and severed distally to the ligation, and 2–3 mm of each nerve was removed distal to the ligation. The sural nerve was preserved, and contact with it was avoided. After these procedures, muscle and skin were closed using 4.0 monofilament nylon sutures and wound clips. The rats were returned to their cages and monitored until they began ambulating. Behavior was evaluated thereafter weekly basis until 4 weeks after SNL or SNI.

Sham-operated rats were subjected to the procedures in the same manner but without nerve ligation or transection. Animals without surgery or manipulation are designated as naïve rats.

2.3. Sensory behavioral testing

Animals were habituated in individual test compartments for at least 1 hour before each testing session. Behavioral tests by mechanical withdrawal threshold testing (von Frey test), noxious punctate mechanical stimulation (Pin test), heat nociception (Hargreaves test), and cold stimulation were performed as previously described. The von Frey test was performed using calibrated monofilaments (Patterson Medical, Bolingbrook, Illinois). Briefly, beginning with the 2.8-g filament, filaments were applied with just enough force to bend the fiber and held for 1 second. If a withdrawal response was observed, the next smaller filament was applied, and if no response was observed, the next larger was applied, until a reversal occurred, defined as a withdrawal after a previous lack of withdrawal, or vice versa. After a reversal event, 4 more stimulations were performed after the same pattern. The forces of the filaments before and after the reversal, and the 4 filaments applied after the reversal, were used to calculate the 50% withdrawal threshold. Rats not responding to any filament were assigned a score of 25 g. Mechanical hyperalgesia (Pin test) was initiated with noxious punctate mechanical stimulation, which was performed using the point of a 22-g spinal anesthesia needle that was applied to the center of plantar surface of the hindpaw with a force that indented the skin without penetration. Five applications were separated by at least 10 seconds, which was repeated after 2 minutes, making a total of 10 touches. For each application, the induced behavior was either a very brisk, simple withdrawal with immediate return of the
foot to the cage floor, or a sustained elevation with grooming that included licking, chewing, and/or shaking, which lasted at least 1 second. We term this latter behavior a hyperalgesic response, which is specifically associated with place avoidance.61 A hyperalgesia score was quantified by tabulating hyperalgesia responses as a percentage of total touches. Heat nociception (Hargreaves test) was performed using a device designed for the purpose of identifying heat sensitivity (Paw Thermal Stimulator System; University Anesthesia Research & Development Group, San Diego, CA). Rats were placed on the temperature-regulated glass platform heated to 30°C, and the hind paw was stimulated with a radiant heat source (50-W halogen bulb) directed through an aperture. In SNI rats, the lateral plantar surface in the sural nerve territory was targeted. The time elapsed from initiation of the stimulus until withdrawal (withdrawal latency) was detected automatically by photocells. Each hind paw was tested 4 times, and the withdrawal latency values averaged. Cold sensitivity was automatically determined using acetone, which was expelled from a syringe attached to PE220 tubing to make a meniscus that was touched with the tubing to the skin. Any induced withdrawal was considered a positive response.19

2.4. Immunohistochemistry and analysis

For immunohistochemistry (IHC), animals were terminally anesthetized, the L5 DRGs as well as the corresponding levels of the spinal cords and the medial plantar skin of hindpaws were dissected, and tissues were postfixed in 10% buffered formalin, followed by paraffin embedding and sectioning. Immunohistochemistry double staining was performed to characterize cellular specificity and distribution of target molecules in sections, as previously described.69 In brief, 5-μm-thick sections were deparaffinized in xylene and rehydrated through graded alcohols, and treated by heat-induced epitope retrieval in 10-mM citrate buffer, pH 6.0–7.0 (depending on the antibody used). Sections were first immunolabeled with the selected primary antibodies overnight at 4°C (Table 1). The specificity of the goat Tmem100 antibody (Santa Cruz Biotechnology, SCB) was tested by preincubating the antibody solution with the specific Tmem100 antigenic peptides (5 μg/mL: SCB) for 2 hours before immunostaining, as described previously.58 The specificities of the other antibodies, including a rabbit anti-Tmem100, a guinea pig anti-TRPV1, and a mouse anti-TRPA1, as well as antibodies of NKAα, GFAP, and Iba1, used in this study, have been previously confirmed by immunostaining and immunoblotting.25,26,58,59,62 All antibodies were diluted in 1× phosphate-buffered saline, containing 0.1% Triton X-100 and 3% bovine serum albumin. Normal immunoglobulin G (from same species as the first antibody) replaced the first antibody for negative controls. The appropriate fluorochrome-conjugated (Alexa 488 or Alexa 594, 1: 2000) secondary antibodies (Jackson ImmunoResearch, West Grove, PA) were used to reveal the binding of immune complexes. The sections were washed 3 times (5 minutes each) with phosphate-buffered saline containing 0.05% Tween-20 between incubations. To stain nuclei, 1.0-μg/mL Hoechst 33342 (Life Technologies, Carlsbad, CA) was added to the secondary antibody mixture. The sections were examined, and images acquired on a Nikon TE2000-S fluorescence microscope (Nikon; El Segundo, CA), equipped with an Optronics Quantifire digital camera and acquisition software (Ontario, NY), as well as filters suitable for selectively detecting the green, red, and blue fluorescence. For each comparative experiment, all images were acquired with identical settings for detector gain and exposure time under a 10× objective (0.5 numerical aperture at 2048 × 2048 pixel resolution) or 20× objective (0.3 numerical aperture at 1024 × 1024 pixel resolution). For double-label colocalization, images from the same section but showing different antigen signals were overlaid.

Quantification of immunopositivity of Tmem100 and markers was performed as described previously.56 In brief, sections were immunostained for Tmem100 and counterstained with Tubul3 or Hoechst (n = 3 DRGs, L4/L5), as well as different markers as indicated. Immunohistochemistry pictures were selected from different levels at 10-section intervals. Cells were considered positive for a marker if their immunoreactive intensity was higher than mean plus 2-fold of SD of negative cells from the sections of negative controls. Percentages of Tmem100-positive cells were obtained by counting the number of Tmem100-positive cells and total positive cells of a given marker. All the counting and measurement, including the cross-sectional area and intensity (mean gray value) of Tmem100 and marker-positive neurons, was performed using Adobe Photoshop CC software. The background for each section was subtracted for intensity quantification. In addition, observer visual annotation (manual) for positive or negative staining was compared with the results of Photoshop software–assisted digital IHC quantification.

Intensity correlation analysis (ICA) was performed to determine colocalization of Tmem100 with neuronal plasma membrane (PM) marker sodium/potassium ATPase 1 alpha (NKAα), SGC marker glial fibrillary acidic protein (GFAP) and glutamine synthetase (GS), and microglia marker–ionized calcium binding adaptor molecule 1 (Iba1) as previously described using an ImageJ 1.46r software plugin (http://imagej.nih.gov/ij/). In brief, fluorescence intensity was quantified in matched region of interests (the green and red colors varied in close synchrony) for each pair of images. Mean background was determined from areas outside the section regions and was subtracted from each file. On the basis of the algorithm, in an image where the intensities vary together, the product of the differences from the mean (PDM) will be positive. If the pixel intensities vary asynchronously (the channels are segregated), then most of the PDM will be negative. The intensity correlation quotient (ICQ) is based on the nonparametric sign-test analysis of the PDM values and is equal to the ratio of the number of positive PDM values to the total number of pixel values. The ICQ values are distributed between –0.5 and +0.5 by subtracting 0.5 from this ratio. In random staining, the ICQ approximates 0. In segregated staining, ICQ is less than 0, whereas for dependent staining, ICQ is greater than 0.56

Tmem100 immunofluorescent intensity was quantified and compared between the ipsilateral and contralateral sides in the dorsal horn of lumbar spinal cord cross sections from SNL animals using ImageJ as described previously.69 In brief, the fluorescence intensity values of ipsilateral and contralateral sides were acquired along a line positioned between the dorsal root entry zone (DREZ), defining the entry surface of primary afferent into the spinal cord, and the central canal in the contralateral and ipsilateral sides of the section (line scan function, scan width 50 pixels). The intensity across the full length of this line was then determined for each section. The average intensity of Tmem100 staining in the superficial dorsal horn (SDH), defined as the region from DREZ to IB4-labeled laminae II inner edge (III), was compared between the ipsilateral and contralateral sides.

Immunocytochemistry (ICC) of Tmem100 expression was performed on rat L4 and L5 DRG cultures dissociated from naive
rats as described previously. Dissociated DRG cells were plated on glass coverslips coated with poly-o-lysine (10 μg/mL; Sigma-Aldrich) for 15 hours and then fixed in 4% paraformaldehyde for 10 minutes. Fixed cells were processed for immunolabelling with a goat Tmem100 (1:100) and a rabbit GFAP (1:1000) or a mouse Tubb3 (1:2000) antibodies at 4°C for overnight, followed by the appropriate fluorophore-conjugated secondary antibodies. After immunostaining and washing, the coverslips were mounted onto glass slides for microscopic observation as above. A time-differential attachment protocol for astrocyte isolation was adapted to establish neuron-free SGC culture. Initially, the dissociated DRG cells were plated on culture dishes for 4 hours for SGC attachment, and then neurons that grow loosely attached to the top of mixed cultures were separated by hand-shaking of the culture flasks gently for 5 to 10 minutes, followed by replacing with new cultural medium.

### 2.5. Immunoblots

The lysates from DRG tissues and HEK293T cells transfected with pCMV-Tmem100 (rat ORF, FN210875; OriGene, Rockville, MD) or pCMV5.0, as well as various cell lines (all from ATCC, Manassas, VA) of F11 (rat DRG neurons), BV2 (mouse microglia), C6 (rat astrocytes), A549 (human non-small-cell lung cancer [NSCLC]), and N2A (mouse brain neurons) were extracted using 1× RIPA buffer (20 mm Tris-HCl pH 7.4, 150 mm NaCl, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% SDS, with 0.1% Triton X100 and protease inhibitor cocktail). As positive and negative controls for Tmem100 expression, 293T cells transfected with the plasmid pCMV-Tmem100 or pCMV5.0 were extracted at the same time. To examine the subcellular localization of Tmem100, DRG tissues were fractionated to obtain PM and cytosolic fractions using the ProteoExtract Subcellular Proteome Extraction Kit (Millipore, Billerica, MA), which contains extraction buffers with ultrapure chemicals to ensure high reproducibility, protease inhibitor cocktail to prevent protein degradation, and benzonase nuclease to remove contaminating nucleic acids, according to the manufacturer’s instructions. Protein concentration was determined using the Pierce BCA kit (ThermoFisher, Pittsburgh, PA). Equivalent protein samples were size separated using 10% or 4% SDS-PAGE gels (Bio-Rad Laboratories, Des Plaines, IL), transferred to 0.22-μm nitrocellulose membranes, and blocked for 1 hour in 5% skim milk. The blots were subsequently incubated overnight at 4°C with a goat anti-Tmem100 (1:400) or rabbit anti-Tmem100 (1:400), a rabbit anti-NKA1α (1:2000), a rabbit anti-GFP (1:2000), a mouse monoclonal anti-NKA1α (1:400), a mouse monoclonal anti-β3-tubulin (tubb3, 1:400), and a mouse monoclonal anti-GAPDH (1:5000). To verify the band specificity of Tmem100 detection using a goat Tmem100 antibody, the antibody solution was preincubuted with the specific Tmem100 antigenic peptides (5 μg/mL; SCB) for 2 hours before immunoblotting. Immunoreactive proteins were detected by Pierce enhanced chemiluminescence (ThermoFisher) after incubation for 1 hour with HRP-conjugated secondary antibodies (1:2000; Bio-Rad). Densitometry of bands of interest was performed using ImageJ v.1.46. Ratios of the band density of the target proteins to the sum of housekeeping gene (Tubb3 or GAPDH) and NKA1α band density were calculated and the percentage changes of target proteins in the experimental samples compared with those from the control samples.

### 2.6. Quantitative real-time PCR analysis

Total RNA was extracted from DRGs using RNAeasy kit (Qiagen, Carlsbad, CA) and then treated with DNase I (Life Technologies). Complementary DNA (cDNA) was synthesized from amounts of

---

**Table 1**

Primary antibodies and IgG controls used in this study.

| Antibody* | Host | Supplier/catalog# | Dilution |
|-----------|------|------------------|----------|
| Tmem100   | Goat polyclonal | SCB/sc-32422 | 1:100 (IHC), 1:400 (Wb) |
| Tmem100   | Rabbit polyclonal | Millipore/ABN1721 | 1:100 (IHC), 1:400 (Wb) |
| IB4       | | ThermoFisher/21413 | 1.0 μg/mL |
| CGRP      | Mouse monoclonal | SCB/sc-57053 | 1:500 (IHC) |
| TRPV1     | Guinea pig polyclonal | Neuronics/GP14100 | 1:100 (IHC), 1:400 (Wb) |
| TRPA1     | Mouse monoclonal | ASB/ARP35205_P050 | 1:100 (IHC) |
| NKA1α     | Mouse monoclonal | SCB/sc-48345 | 1:400 (IHC and Wb) |
| PKCγ      | Rabbit polyclonal | SCB/sc-211 | 1:100 (IHC) |
| Tubb3     | Mouse monoclonal | SCB/sc-80016 | 1:400 (IHC) |
| NF200     | Mouse monoclonal | Sigma/14142 | 1:1000 (IHC) |
| 2A peptide| Rabbit polyclonal | Millipore/AB331 | 1:400 (Wb) |
| GFAP      | Rabbit polyclonal | Dako/20334 | 1:1000 (IHC), 1:2000 (Wb) |
| GS        | Rabbit polyclonal | SCB/sc-6640R | 1:600 (IHC) |
| Iba1      | Rabbit polyclonal | Wake/019-19741 | 1:1000 (IHC), 1:2000 (Wb) |
| GAPDH     | Mouse monoclonal | PT/2555 | 1:5000 (Wb) |
| IgG control | Mouse | LF/31903 | 1:100—400 |
| IgG control | Goat | LF/31345 | 1:100—200 |
| IgG control | Rabbit | LF/MA5-16384 | 1:100—1000 |

* CGRP, calcitonin gene-related peptide; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFAP, glial fibrillary acidic protein; GS, glutaminesynthetase; Iba1, ionized calcium binding adaptor molecule 1; NKA1α, sodium potassium ATPase A1α; PKCγ, protein kinase C gamma; Tmem100, transmembrane protein 100; TRPA1, transient receptor potential anion channel subfamily A member 1; TRPV1, transient receptor potential cation channel subfamily V member 1; Tubb3, β3-tubulin.
† SCB, Santa Cruz Biotechnology, Santa Cruz, CA; Millipore, Billerica, MA; ThermoFisher, Pittsburgh, PA; Neuromics, Edina, MN; ASB, Aviva Systems Biology, San Diego, CA; Dako, Carpinteria, CA; PT, Proteintech, Rosemont, IL; Life Technologies, Carlsbad, CA; Sigma, Sigma-Aldrich, St Louis, MO; AA, Atlas Antibodies, Stockholm, Sweden.
RNA that were standardized for each experiment using the Superscript III first strand synthesis kit with random hexamer primers (Life Technologies). Quantitative PCR was performed using IQ Syber Green supermix (Bio-Rad) on a Bio-Rad CFX96 Real-time PCR Machine and specific intron-spanning primers from rat to quantitate the mRNA levels of Tmem100 and GAPDH. Tmem100 primers: forward 5'-CTGCCGAAGGCTCATTGGC-3', reverse 5'-AGACAGCCGCATCCCTTG-3', and GAPDH primers: forward 5'-AGACAGCCGCATCTTGTTG-3', reverse 5'-TGATGGCAACAATGTCCACT-3'. The thermal cycling conditions were 1 cycle at 95°C for 1 minute, 40 cycles at 95°C for 15 seconds, and 1 cycle at 60°C for 15 seconds. For each sample, 2 inter-run determinations were performed, and 2 replicates in each run were averaged. GAPDH, which has been verified as the least affected reference gene at the mRNA level in the setting of nerve injury in our previous study, was used as the housekeeping gene for calculation of fold differences in expression of Tmem100 mRNA. The relative amount of mRNA transcript in the samples of the axotomized L5-DRGs from L5-SNL rats and the ipsilateral L5-DRGs from CFA rats to control DRGs (contralateral) was measured by 2^-ΔΔCt calculation, where ΔΔCt = (Ct Tmem100 - Ct GAPDH)ipsi.L5-DRG - (Ct Tmem100 - Ct GAPDH)contra.DRG.

3. Results

3.1. Identification of Tmem100 expression in neurons and glial cells in rat dorsal root ganglion

We first tested the suitability of 2 established antibodies for use in determining DRG expression of Tmem100 in rats. In DRGs from naive rats, IHC analysis on antigen-retrieved parafin-sections detected a broad Tmem100 expression profile using a Tmem100 polyclonal antibody generated in goat against Tmem100 protein N-terminal 15aa fragment of mouse origin (Fig. 1A). This antibody has been verified for its specificity and applied to detect Tmem100 expression in mouse myenteric neurons and human hepatocellular carcinoma tissues in previous publications. Here, Tmem100 immunoreactivity (IR) stained the full profile of small- and middle-sized neurons, but in contrast displayed “ring-like” profiles in the case of large-sized neurons, in a pattern that could represent Tmem100 immunopositivity in neuronal membranes, SGCs, or both (Fig. 1A, B, B1). By immunoblot, the antibody revealed a clean band around ~17 KDa (i.e., slightly greater than apparent molecular mass of 14.5 KDa) as the target protein in the homogenates of DRGs from adult rats, which aligns with the size of the positive band in the lysates from Tmem100-cDNA–transfected HEK293T cells. This protein band was not detected in the sham-transfected cells (Fig. 1C). Preincubation with excess immunogenic peptide completely eliminated the band in immunoblots (Fig. 1D) and eliminated IHC staining in sections (data not shown). Tmem100-IR was also detected in the lumbar SDH (Fig. 1E), spanning from the DREZ to the laminae II inner ventral edge (llv) defined by the PKCγ-labeled intrinsic SDH neurons (Fig. 1F), therefore including the distribution of the terminations of the CRGP-positive primary afferents in laminae I (Fig. 1G) and the isolectin B4 (IB4)-positive afferents terminating in laminae II (Fig. 1H). Tmem100 showed no expression in intrinsic dorsal horn neurons labeled with PKCγ, suggesting that Tmem100 is synthesized in sensory neuron somata and transported to their central terminals in the DH superficial laminae. No immunostaining signals were observed when the first antibodies used were replaced by immunoglobulin G from the same species, or the second antibody was omitted, supporting the specific immunopositivity of IHC detection (Supplemental Fig. S1, available at http://links.lww.com/PR9/A37). Tmem100 was not identified in skin sections from the hind paw (data not shown) by our current IHC techniques. In a second antibody trial, we also used a rabbit Tmem100 polyclonal antibody raised by an immunogenic peptide corresponding to N-terminal 19aa sequence of mouse Tmem100 with the specificity verified in a previous report. This rabbit antibody showed sensitive
Tmem100 protein detection as a clean ~17 KDa band by immunoblot (Supplemental Fig. S2A, available at http://links.lww.com/PR9/A37). IHC with this antibody (Supplemental Fig. S2B, C, available at http://links.lww.com/PR9/A37) showed a pattern similar to that using the goat antibody, but seemed somewhat less sensitive for detecting Tmem100. Based on these results, our subsequent experiments used the goat polyclonal antibody to detect Tmem100 protein in the tissue sections and DRG-dissociated culture by IHC and ICC, and the rabbit polyclonal antibody was used for immunoblotting to detect Tmem100 expression in DRG tissue.

Tmem100 has been reported to be widely expressed in multiple tissues, but the cellular and subcellular distribution and specificity of Tmem100 expression in rat DRGs remain undefined. We therefore next determined the phenotype of small-sized neurons that express Tmem100 using IB4 as a marker for nonpeptidergic small neurons and CGRP as a marker for peptidergic small neurons. We observed high expression of Tmem100 in both IB4-positive and CGRP-positive neurons. An average of 97% ± 1% of Tmem100-positive neurons bound IB4 and 83% ± 6% of IB4-positive neurons expressed Tmem100. On average, 74% ± 13% of Tmem100-positive neurons expressed CGRP, whereas 48% ± 6% of CGRP-positive neurons expressed Tmem100 (Fig. 2A, A1, B, B1). In addition, Tmem100 is highly colocalized with TRPV1 (94% ± 5%) and TRPA1 (96% ± 3%) (Fig. 2C, C1, D, D1). Some small neurons showed a characteristic punctate Tmem100 immunopositivity suggesting subcellular localization (Fig. 2E, F). Approximately 30%-40% of IB4 or CGRP neurons are also positive for both CGRP and IB4 (Fig. 2G, G1) similar as previously reported, suggesting that Tmem100 can be expressed in IB4/CGRP double-positive neurons. These results together indicate that Tmem100 is abundantly expressed in the nonmyelinated C-fiber or lightly myelinated Aδ-fiber nociceptive neuron populations, with both neuronal membrane and intracellular localizations.

To identify whether the encircling profile of Tmem100 expression around large neurons consists of expression in neuronal PM or surrounding SGCs, we performed double immunolabeling of Tmem100 with either a canonical neuronal PM marker (NKA1α), SGC marker (GFAP or GS), or a microglia marker (Iba1), using antibodies for which the specificities were optimized (Supplemental Fig. 3, available at http://links.lww.com/PR9/A37), similar to our previous reports. Overlaid images of Tmem100 with NKA1α and pixel intensity line-plot profiles of cross-sections clearly identified neuronal PM localization of Tmem100 in these neurons (Fig. 3A–A2, B–B3, C). We also used the ICA method to analyze the extent of immunocolocalization between Tmem100 and NKA1α. Intensity correlation analysis plots of Tmem100 and NKA1α were strongly skewed toward positive values with the calculated ICQ value 0.248 (P = 0.001), consistent with colocalization. These data thus suggest that at least a portion of the Tmem100 expression around the large-sized neurons is within the neuronal PM. In
addition, however, partial or complete colocalization was also clearly delineated in the overlaid images of Tmem100 and GFAP or GS double immunolabeling, especially those encircling the large diameter neurons (Fig. 4A–D). To further verify the SGC expression of Tmem100, ICA was performed to analyze the immunocolocalization between Tmem100 and GFAP or GS. The ICA plots of Tmem100 and GFAP or GS were strongly skewed toward positive values (Fig. 4E, F), consistent with colocalization in SGCs, and the ICQ values were positive. Some overlay was also observed in double labeling images of Tmem100 with Iba1 in naive DRG sections (Fig. 4G–4I), with ICQ values indicating colocalization (Fig. 4H1, I1). These data thus suggest that Tmem100 is expressed in the perineuronal SGCs and in some of the DRG-resident microglia. Neuronal and SGC expression of Tmem100 was also confirmed by ICC double labeling of Tmem100 with markers on DRG-dissociated cultures (Supplemental Fig. S4, available at http://links.lww.com/PR9/A37).

Tmem100 expression has been identified in neural stem cells, neurons, astrocytes, and microglia of CNS origin.\(^7,10,27,28,38,52,57\) We also detected Tmem100 expression by immunoblot of lysates from various cell lines (Supplemental Fig. S5, available at http://links.lww.com/PR9/A37), including F11 (derived from rat DRG neurons), BV2 (from mouse microglia), C6 (from rat astrocytes), and N2A (from mouse brain cortex neurons). These observations indicate that a broad range of cell types express Tmem100. A weak Tmem100 band was also detected in the lysate of non-neuronal A549 cells (derived from human NSCLCs).

3.2. Increased dorsal root ganglion Tmem100 expression in inflammatory pain

Our experiments performed up to this point establish that Tmem100 is extensively expressed in neurons and glial cells in the normal rat DRG. We then asked how Tmem100 expression in
the different cell populations is altered in painful conditions. In addition, because Tmem100 is differentially expressed in the PM of sensory neurons, we separately quantified Tmem100 in the NKA1α-enriched membrane fraction vs the NKA1α-deficient soluble fraction, hereafter referred to as PM and cytosolic fractions. These were extracted from the lumbar DRG tissues followed by immunoblotting of Tmem100 protein levels in these fractions.

We used peripheral injection of CFA as a model of inflammatory pain. As expected, inflammatory pain was successfully induced by intraplantar injection of CFA in the right hindpaw, as demonstrated by marked cutaneous edema and redness of injected hindpaw and the significantly reduced threshold for withdrawal from mild mechanical stimuli (von Frey) and PWL when compared with animals receiving only saline injection (Fig. 5A, B). Signs of inflammation lasted throughout the 10-day testing duration.

By semiquantitative IHC staining, a previous report observed an increase in the percentage of Tmem100-expressing DRG neurons in the CFA-inflammatory pain mouse model. We also observed an increased Tmem100 expression profile after CFA using IHC (Fig. 5C, D). Tmem100 is a putative PM-localized protein, but its subcellular localization by immunoblot has not been investigated. To gain information on the association and alteration of Tmem100 localization, the NKA1α-enriched membrane fraction and NKA1α-lacking soluble fraction were extracted from the lumbar DRG tissues harvested 10 days after CFA injection. Immunoblot results showed that Tmem100 was found in both PM and cytosolic fractions in the control DRGs, and that Tmem100 level from the DRGs ipsilateral to CFA injection was significantly higher in both fractions than those of control tissues (Fig. 5E, F). No significant differences were noted for GFAP protein levels by Western blot analysis between the ipsilateral DRGs harvested at the 10 days after CFA and controls.

Figure 3. IHC delineation of Tmem100 localization to the PM in primary sensory neurons. Representative montage images show immunostaining of Tmem100 (green) with a canonical neuronal PM marker NKA1α (red) showing colabeling (yellow) in the merged image (A–A2, B–B3). Pixel intensity line-plot profiles of crossed sections clearly indicate neuronal PM localization of Tmem100 in the larger neurons (B, B1, C). ICA colocalization: Scatter plots for the region demarcated by the white dashed line in (B3) panel show strong right skewing for NKA1α (D) and Tmem100 (E). In (D, E), “A” is the intensity of Tmem100 while “a” is the average of these values, and “B” is the intensity of NKA1α while “b” is the average of these values. For this region, the intensity correlation quotient (ICQ) value is 0.248 (P_{sign test} < 0.001), indicating immunocolocalization. Scale bars: 100 μm for all. ICA, intensity correlation analysis; IHC, immunohistochemistry; PM, plasma membrane.
Tmem100 mRNA level was also significantly increased in the DRGs ipsilateral to CFA injection (Fig. 5G). These data are consistent with a previous report showing an upregulation of Tmem100 protein level in DRGs after CFA-inflammatory pain. And the upregulation of Tmem100 expression is likely due to increased de novo biosynthesis from neurons because Tmem100 transcript is also upregulated.

### 3.3. Decreased dorsal root ganglion Tmem100 expression in neuropathic pain

After nerve injury by SNL, sensory testing revealed the expected pain behavior, which included reduced threshold for withdrawal from von Frey testing representing mechanical allodynia, exaggerated, and sustained responses to noxious mechanical stimulation (Pin testing) representing mechanical hyperalgesia.
and increased sensitivity to heat and cold stimulation representing thermal hypersensitivity. These changes lasted throughout the 4-week testing interval (Fig. 6A–A3).

Immunoblot analysis of Tmem100 levels using DRGs harvested 28 days after SNL revealed a clean band at ~17 KDa in the PM and cytosolic fractions extracted from the contralateral DRGs. However, the Tmem100 protein level in the ipsilateral L5 DRGs were significantly decreased to 11.3% ± 1.2% in the PM fraction and 10.5% ± 6.4% in the cytosolic fractions, normalized to the corresponding fractions from contralateral L5 DRGs, whereas Tmem100 levels in both fractions from the noninjured L4 DRGs did not change compared with the contralateral levels (n = 9 DRGs in each group). Iba1 (a PM and cytoplasm colocalized protein) and GFAP (a cytoskeleton protein) were found in both PM and cytosolic fractions, and their levels were increased not only in the injured L5 DRGs but also in the noninjured L4 DRGs, compared with the contralateral DRGs (Fig. 6B, B1, C, C1).

These results indicate that the spared L4 DRGs, although not axotomized, developed changes resembling inflammatory responses, which has been reported previously. Elevated Iba1 and GFAP protein levels reflect the proliferation SGCs and resident microglia, so the lack of Tmem100 elevation suggests that Tmem100 expression in these glial cells of axotomized L5-DRGs was also likely suppressed. We also examined Tmem100 mRNA expression in the axotomized L5-DRGs at 4 weeks after SNL compared with the contralateral DRGs by qPCR. In contrast...
to protein levels, we observed slightly elevated but not significant changes of Tmem100 mRNA levels in the injured L5 DRGs (Fig. 6D).

The concordant neuron and SGC downregulation of Tmem100 expression in the axotomized L5-DRGs was verified by IHC analysis performed on DRGs 4 weeks after SNL. These IHC images showed that Tmem100-IR intensity for glial cells, and all neuronal size groups were diminished in the ipsilateral L5 DRGs (Fig. 7, cf. A, C, E in control to B, D, F in SNL). Injury-induced loss of Tmem100 in the DRG paralleled with loss of IB4

Figure 6. Behavior and immunoblot analysis of Tmem100 expression in DRGs after SNL. Rats with L5-SNL developed mechanical allodynia (von Frey, A), hyperalgesia (Pin, A1), Heat (A2), and Cold (A3) hypersensitivity, *P < 0.05, **P < 0.01, and ***P < 0.001 for comparison to baseline (BL) and #P < 0.05, ##P < 0.01, and ###P < 0.001 for comparison between groups at 2 and 4 weeks after SNL, respectively. The NKA1α-eliminated cytosol and NKA1α-enriched PM protein fractions were extracted from the DRG tissues at 28 days after L5-SNL and control samples, and subjected to immunoblotting as shown in the representative immunoblots of Tmem100, Iba1, GFAP, NKA1α, and Tubb3 of cytosol (B) and PM fractions (B1), respectively. Bar charts in the panels (C, C1) are the results of densitometry analysis of immunoblots (**P < 0.001). The number in each bar is the number of analyzed DRGs per group. Bar chart in the panel (D) is the result of qPCR quantification of Tmem100 mRNA in the L5 DRGs from ipsilateral (i) and contralateral (c) to SNL at 28 days after injury (n = 4 per groups). DRG, dorsal root ganglion; GFAP, glial fibrillary acidic protein; PM, plasma membrane; SNL, spinal nerve ligation.
binding (and CGRP staining, data not shown) and increased GFAP and Iba1 immunostaining. As with our Western data, although GFAP and Iba1 protein staining was markedly increased, likely reflecting injury-induced neural inflammatory response, the Tmem100 protein was lost, further supporting diminished Tmem100 protein expression in both neurons and glial cells after axotomy. In parallel, Tmem100-IR in the ipsilateral lumbar SDH in SNL rats was significantly reduced (Fig. 7G–I), compared to that in the contralateral site.

To further confirm that peripheral nerve injury downregulates Tmem100 protein levels, we performed immunoblots from DRGs after injury by the SNI model of neuropathic pain, which results in DRGs containing commingled axotomized and noninjured neurons. These rats developed painful mechanical allodynia (von Frey) and hyperalgesia (Pin) (Fig. 8A, A1) during 4 weeks after SNI. Dorsal root ganglia processed for PM and cytosolic fractionation produced immunoblots that showed depressed Tmem100 protein levels in both PM and cytosolic fractions extracted from the SNI-DRGs compared with the control DRGs (contralateral) (Fig. 8B, C). Immunohistochemistry staining delineated downregulation profile of Tmem100 in both neurons and SGCs with apparently decreased CGRP staining and increased Iba1 and GFAP staining in DRG sections from SNI rats, compared with controls (Fig. 8D–I).

Together, these data indicate that painful peripheral nerve injury induces significant downregulation of Tmem100 protein expression in DRG neurons and glial cells, although the latter cell populations are highly proliferated and activated after nerve injury.

3.4. Overexpression of Tmem100 inhibits astrocyte, microglia, and satellite glial cell proliferation

Previous works indicate a role of Tmem100 in controlling cell proliferation.21,26,45,65 Our data suggest that increased proliferation of DRG SGCs and resident microglia after nerve injury was associated with downregulation of SGC-Tmem100 in SNL and SNI rats. To test the hypothesis that Tmem100 might play
a transregulator role for glial cell proliferation, we generated LV expressing Tmem100 or EGFP as control and infected C6 astrocytes and BV2 microglial cell lines (representative of DRG SGCs and microglia, respectively), which resulted in a successful transduction rates of 95% in both C6 and BV2 cell lines. CCK8 assay was used to detect the effect of proliferation after overexpression of Tmem100 or EGFP in these cell lines. Results showed that LV-mediated Tmem100 overexpression significantly inhibited C6 astrocytes (Fig. 9A–C) and BV2 microglia (Fig. 9D–F) proliferation, compared with LV-EGFP infected cells. Inhibition of cell proliferation by Tmem100 was further tested in the isolated neuron-free SGCs from naive rats. An approximately 90% transduction rate of SGCs was found by both LV-Tmem100 and LV-EGFP 4 days after addition of the vector. The growth rate of SGCs 4 days after infected by LV-Tmem100 was significantly slower than that of the SGCs infected by LV-EGFP (Fig. 9G–I).

4. Discussion
Tmem100 has been reported to be widely expressed in multiple mammalian tissues, with high abundance in lung and arterial endothelium.26,41 Tmem100 is also found in neurons and glial cells of the CNS and in the peripheral nervous system.16,59 Here, we report expression of Tmem100 in multiple cell types in the adult rat DRG. Specifically, we demonstrate that Tmem100 is expressed in the full range of primary sensory neuron populations, including the IB4-positive nonpeptidergic and CGRP-positive peptidergic small neurons, as well as the medium- and large-diameter neurons. Tmem100 is highly colocalized with TRPV1 and TRPA1 and is found in both PM and intracellular compartments in smaller neurons. In large neurons, Tmem100 is enriched in the PM, with immunopositivity in close apposition to surrounding SGCs that themselves robustly express Tmem100. This localization of Tmem100 expression in both the PM and...
Figure 9. Effect of overexpression of Tmem100 on astrocyte, microglia, and SGC proliferation. EGFP or EGFP2ATmem100 (green) expression with ICC detected Tmem100 (red) and merged images as indicated in C6 astrocytes 4 days after transduction by LV-EGFP, MOI = 5 (top panels) and LV-Tmem100, MOI = 5 (bottom panels) (A, scale bar: 25 μm for all). Western blots show expression of EGFP (top), 2A (middle), and Tmem100 in C6 astrocytes transduced by LV-Tmem100 (B). Overexpression of Tmem100 significantly inhibits cell proliferation of C6 astrocytes, compared with the cells transduced by LV-EGFP control vector (C). EGFP or GFP2ATmem100 (green) expression with ICC detected Tmem100 (red) and merged images in BV2 microglia 4 days after transduction by LV-EGFP, MOI = 5 (top panels) and LV-Tmem100, MOI = 5 (bottom panels) (D, scale bar: 25 μm for all). Western blots show expression of EGFP (top), 2A (middle), and Tmem100 in BV2 microglia transduced by LV-Tmem100 (E). Overexpression of Tmem100 significantly inhibits cell proliferation of BV2 microglia, compared with the cells transduced by LV-EGFP control vector (F). Montage images (G) show EGFP or EGFP2ATmem100 (green), SGC morphology (phase), and merged images, as well as Tmem100 ICC in the primary SGCs after transduction by LV-EGFP, MOI = 5 (top panels) and LV-Tmem100, MOI = 5 (bottom panels). Cell proliferation analyzed by CCK8 assay is significantly slower in the LV-Tmem100–transduced SGCs, compared with LV-EGFP–infected cells (I). *P < 0.05, **P < 0.01, and ***P < 0.001. The numbers in each bar in panels (C, F, I) indicate the repeats of CCK8 assay. ICC, immunocytochemistry; MOI, multiplicity of infection; SGC, satellite glial cell.
cytosolic fractions is also verified by immunoblot analysis. Finally, we also identify Tmem100 expression in a small subset of resident microglia in the control DRG. Therefore, building on previous findings that characterize Tmem100 expression using EGFP as a marker based on a BAC Tmem100-EGFP mouse line, our results add new insights to the Tmem100 expression profile by directly detecting Tmem100 expression using a highly specific Tmem100 antibody. Although we detect Tmem100 in most IB4-neurons and in CGRP neurons in rat DRG using 2 distinct antibodies, a prior report described minimal expression of Tmem100 in IB4-binding neurons. It is reported that a substantial of nociceptive neurons in adult rat DRG is double positive for both IB4 and CRRP, but the overlay is much less in mouse. Thus, the discrepancy between 2 studies may be the result of different experimental conditions and approaches including antibody difference, IHC methods (cryosection vs paraffin-section with antigen retrieval process), and possible species differences between rat and mouse.

Our data indicate that painful conditions are accompanied by divergent alterations of Tmem100 expression in a pathology-dependent manner, with upregulation after CFA-inflammatory pain, as in a previous study, but dramatic downregulation in the injured DRGs after peripheral nerve injury. Thus, the role played by Tmem100 in the development of pain likely differs between neuropathic and inflammatory mechanisms. This is reminiscent of a similar divergence of the effects of inflammation vs axotomy on other sensory neuron properties, including expression levels of voltage-gated Ca\textsuperscript{2+} and Na\textsuperscript{+} currents. The percentage of CGRP-positive DRG neurons is consistently increased in various inflammatory pain models, accompanied by functional activation of CGRP\textsuperscript{+} and IB4\textsuperscript{+} neurons. Further study is needed to determine how this change correlates temporally with the development of pain behavior after injury, and whether this nerve injury–induced Tmem100 downregulation would reverse in a longer timeframe because pain behavior and altered gene expression may eventually recover after nerve injury. In addition, the unaffected level of Tmem100 mRNA level in the axotomized DRGs suggests that the diminished Tmem100 protein expression after nerve injury may be the result of a translational repression of Tmem100 mRNA or rapid Tmem100 protein turnover, rather than DRG cell death after injury. It is reported that neuronal excitation in an in vitro coculture system suppresses astrocyte gene expression, including Tmem100, so neuronal hyperexcitability after nerve injury could be a contributing factor in Tmem100 loss after nerve injury.

Previous research has characterized the molecular function of Tmem100 in modulating TRPV1 and TRPA1 association in primary sensory neurons. However, there is as yet no evidence of TRPV1–TRPA1 interaction in SGCs. Thus, the presence of Tmem100 in SGCs adds another site for the potential roles of Tmem100 in neuropathic pain. Furthermore, a recent report found that Tmem100 is not restricted to the neurons coexpressing TRPV1 and TRPA1, suggesting that Tmem100 may serve other functions unrelated to these receptors, perhaps by interacting with additional nociceptive transducers.

Although nerve injury results in proliferation and activation of glial cell populations, our data indicate that the normal expression of Tmem100 by these non-neuronal cells is nonetheless suppressed in this setting. There is growing evidence of the involvement of Tmem100 in controlling developmental proliferation and differentiation. For instance, Tmem100 is involved in the pathways activated by the TGFβ/BMPs/activin family of signaling molecules that are critical in developmental cellular differentiation. Tmem100 has also been linked to cell proliferation and apoptosis of various tumor cells and tumor-derived neuronal cells. For instance, Tmem100 expression is significantly downregulated in human hepatocellular carcinoma, NSCLC, and glioblastoma, whereas overexpression of Tmem100 in NSCLC cell lines inhibits tumor cell proliferation. Together, these studies suggest that Tmem100 may act as an important cell proliferation regulator. We also found that viral-mediated overexpression of Tmem100 in astrocyte and microglia cell lines and in SGCs isolated from rat DRG significantly blunt their proliferation in culture. These data suggest that Tmem100 likely plays a role in control SGC proliferation and also suggest that nerve injury–induced downregulation of SGC-Tmem100 by an undefined mechanism may possibly be correlated with increased SGC proliferation in animals with painful nerve injury. Although the direct effect of Tmem100 on SGC function is yet to be determined in vivo, downregulation of Tmem100 may be considered as a cause of SGC proliferation and pain after nerve injury. If this causal link is confirmed, then overexpression Tmem100 in SGCs might provide analgesia after nerve injury by reducing SGC proliferation/activation. By contrast, the opposite may be true in inflammatory pain, for which downregulating its expression or interfering in its function in neurons may be analgesic.

In conclusion, this study reports that Tmem100 is expressed in multiple cell types in rat DRGs, including the full range of sensory neuron populations, as well as SGCs and resident microglia. Because Tmem100 protein expression is diminished in neuropathic pain models, manipulation of this signaling pathway may be a means of controlling clinical neuropathic pain.

Disclosures
The authors have no conflict of interest to declare.

Acknowledgment
This research was supported by a grant from the Department of Veterans Affairs Rehabilitation Research and Development (I01RX001940 to Q. H. Hogan). Y. Cai was a recipient of Chinese Scholarship Council.

Appendix A. Supplemental digital content
Supplemental digital content associated with this article can be found online at http://links.lww.com/PRR/A37.

Article history:
Received 8 March 2018
Received in revised form 8 October 2018
Accepted 30 October 2018

References
[1] Aoki Y, Ohtori S, Takahashi K, Imo H, Takahashi Y, Chiba T, Moriya H. Innervation of the lumbar intervertebral disc by nerve growth factor-dependent neurons related to inflammatory pain. Spine (Phila Pa 1976) 2004;29:1077–81.
